Patents by Inventor Yuxiao Wang

Yuxiao Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MACROPHAGE SPECIFIC ENGAGER COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20220241428
    Abstract: The present disclosure provides compositions and methods for making and using therapeutic agents comprising myeloid cell specific engagers, used for immunotherapy of cancer or infection.
    Type: Application
    Filed: June 11, 2020
    Publication date: August 4, 2022
    Inventors: Daniel GETTS, Yuxiao Wang
  • METHODS AND COMPOSITIONS FOR GENOMIC INTEGRATION
    Publication number: 20220184230
    Abstract: Methods and composition for modulating a target genome and stable integration of a transgene of interest into the genome of a cell are disclosed.
    Type: Application
    Filed: March 4, 2022
    Publication date: June 16, 2022
    Inventors: Daniel Getts, Yuxiao Wang, Namita Bisaria
  • ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20220152199
    Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.
    Type: Application
    Filed: February 1, 2022
    Publication date: May 19, 2022
    Inventors: Daniel GETTS, Yuxiao Wang, Bruce McCreedy, JR.
  • ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20220001031
    Abstract: The present disclosure provides compositions and methods for making and using engineered phagocytic cells that express a chimeric antigen receptor having an enhanced phagocytic activity for immunotherapy in cancer or infection.
    Type: Application
    Filed: August 17, 2021
    Publication date: January 6, 2022
    Inventors: Daniel GETTS, Yuxiao Wang
  • THERAPEUTIC CELL COMPOSITIONS AND METHODS OF MANUFACTURING AND USE THEREOF
    Publication number: 20210361703
    Abstract: The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.
    Type: Application
    Filed: March 15, 2021
    Publication date: November 25, 2021
    Inventors: Daniel Getts, Yuxiao Wang
  • ENGINEERED PHAGOCYTIC RECEPTOR COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20210299172
    Abstract: The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.
    Type: Application
    Filed: March 23, 2021
    Publication date: September 30, 2021
    Inventors: Daniel Getts, Yuxiao Wang
  • Engineered phagocytic receptor compositions and methods of use thereof
    Patent number: 11026973
    Abstract: The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: June 8, 2021
    Assignee: Myeloid Therapeutics, Inc.
    Inventors: Daniel Getts, Yuxiao Wang
  • Engineered phagocytic receptor compositions and methods of use thereof
    Patent number: 11013764
    Abstract: The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: May 25, 2021
    Assignee: Myeloid Therapeutics, Inc.
    Inventors: Daniel Getts, Yuxiao Wang
  • Therapeutic cell compositions and methods of manufacturing and use thereof
    Patent number: 10980836
    Abstract: The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: April 20, 2021
    Assignee: Myeloid Therapeutics, Inc.
    Inventors: Daniel Getts, Yuxiao Wang
  • ENGINEERED PHAGOCYTIC RECEPTOR COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20200345774
    Abstract: The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.
    Type: Application
    Filed: March 23, 2020
    Publication date: November 5, 2020
    Applicant: Myeloid Therapeutics, Inc.
    Inventors: Daniel Getts, Yuxiao Wang
  • ENGINEERED PHAGOCYTIC RECEPTOR COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20200345773
    Abstract: The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.
    Type: Application
    Filed: March 23, 2020
    Publication date: November 5, 2020
    Inventors: Daniel Getts, Yuxiao Wang